gentamicin sulfate

CLINICAL PHARMACOLOGY:

Microbiology:

Gentamicin sulfate is active in vitro against many strains of the following microorganisms:

Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Streptococcus pneumoniae , Enterobacter aerogenes , Escherichia coli, Haemophilus influenzae , Klebsiella pneumoniae , Neisseria gonorrhoeae , Pseudomonas aeruginosa , and Serratia marcescens .

INDICATIONS AND USAGE:

Gentamicin Ophthalmic Ointment is indicated in the topical treatment of ocular bacterial infections, including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis caused by susceptible strains of the following microorganisms:

Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Streptococcus pneumoniae , Enterobacter aerogenes , Escherichia coli, Haemophilus influenzae , Klebsiella pneumoniae , Neisseria gonorrhoeae , Pseudomonas aeruginosa , and Serratia marcescens .

CONTRAINDICATIONS:

Gentamicin Ophthalmic Ointment is contraindicated in patients with known hypersensitivity to any of the components.

WARNINGS:

NOT FOR INJECTION INTO THE EYE. Gentamicin Sulfate Ophthalmic Ointment is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.

PRECAUTIONS

General:

Prolonged use of topical antibiotics may give rise to overgrowth of non-susceptible organisms including fungi. Bacterial resistance to gentamicin may also develop. If purulent discharge, inflammation or pain becomes aggravated, the patient should discontinue use of the medication and consult a physician.

If irritation or hypersensitivity to any component of the drug develops, the patient should discontinue use of this preparation, and appropriate therapy should be instituted.

Ophthalmic ointments may retard corneal healing.

Information for Patients:

To avoid contamination, do not touch tip of container to the eye, eyelid, or any surface.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

There are no published carcinogenicity or impairment of fertility studies on gentamicin. Aminoglycoside antibiotics have been found to be non-mutagenic.

Pregnancy:

Pregnancy Category C.

Gentamicin has been shown to depress body weights, kidney weights, and median glomerular counts in newborn rats when administered systemically to pregnant rats in daily doses approximately 500 times the maximum recommended ophthalmic human dose. There are no adequate and well-controlled studies in pregnant women. Gentamicin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Safety and effectiveness in neonates have not been established.

ADVERSE REACTIONS:

Bacterial and fungal corneal ulcers have developed during treatment with gentamicin ophthalmic preparations.

The most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non-specific conjunctivitis, conjunctival epithelial defects, and conjunctival hyperemia.

Other adverse reactions which have occurred rarely are allergic reactions, thrombocytopenic purpura, and hallucinations.

To report SUSPECTED ADVERSE REACTIONS, contact Perrigo at 1-800-328-5113, or FDA at

1-800-FDA-1088 or www.fda.gov/medwatch.

DOSAGE AND ADMINISTRATION:

Apply a small amount (about 1/2 inch) to the affected eye(s) two to three times a day.

HOW SUPPLIED:

Gentamicin Ophthalmic Ointment USP is supplied in 3.5 g (1/8 oz) sterile tamper evident tubes with ophthalmic tip.

NDC 0574-4102-35

Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].

Manufactured For

Perrigo®

Minneapolis, MN 55427

8Z900 RC J1 Rev 07-13 A Ini 0713 R0713

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – Carton

Rx Only

NDC 0574-4102-35

Gentamicin Sulfate Ophthalmic Ointment USP, 0.3%

Gentamicin Sulfate, USP equivalent to 3 mg gentamicin base per gram.

Net wt. 3.5 g (1/8 oz)

STERILE